WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Eloralintide

Governed registry record

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept.

    DOI: 10.1016/j.molmet.2025.102271

    Source identity and connection checked by Codex (AI).

  2. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.

    DOI: 10.1016/s0140-6736(25)02155-5

    Source identity and connection checked by Codex (AI).

  3. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept.

    DOI: 10.1111/dom.70439

    Source identity and connection checked by Codex (AI).

  4. Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

    DOI: 10.1016/j.peptides.2026.171480PMID: 41747885

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Bhattachar S
  • Tham LS
  • Tidemann-Miller B
  • Ibriga H
  • Qu H
  • Briere DA
  • Haupt A
  • Mather KJ
  • Pratt E
  • Billings LK
  • Hsia S
  • Bays H
  • O'Hagan J
  • Butler A
  • Kazda C
  • Coskun T
  • Lansu K
  • He MM
  • Moyers JS
  • Long A
  • Allen D
  • O'Farrell L
  • Bowen B
  • Alsina-Fernandez J
  • Bhattachar SN
  • Bailey CJ
  • Flatt PR
  • Conlon JM